UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2024

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number: 000-30991

SKINOVATION PHARMACEUTICAL INCORPORATED

(Exact name of registrant as specified in its charter)

Wyoming (State or other jurisdiction of incorporation or organization)	87-0458170 (I.R.S. Employer Identification No.)
440 East 400 South Ste 300, Salt Lake City, Utah (Address of principal executive offices)	84111 (Zip Code)
440 East 400 South, Ste 300, Salt Lake City, Utah (Address of principal executive offices)	84111 (Zip Code)

(801) 323-2395

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Non-accelerated filer ☑

Accelerated filer ☐

Smaller reporting company ☑

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☑ No ☐

The number of shares outstanding of the registrant’s Common ~~common~~Stock ~~stock~~ as of ~~August~~November 1219, 2024 was 708,000.

TABLE OF CONTENTS

	PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	3
	Condensed Balance Sheets (Unaudited)	4
	Condensed Statements of Operations (Unaudited)	5
	Condensed Statements of Stockholders' Deficit (Unaudited)	6
	Condensed Statements of Cash Flows (Unaudited)	7
	Notes to the Unaudited Condensed Financial Statements	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	11
Item 4.	Controls and Procedures	11

	PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	12
Item 1a.	Risk Factors Information	12
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	12
Item 3.	Defaults Upon Senior Securities	12
Item 4.	Mine Safety Disclosures	12
Item 5.	Other Information	12
Item 6.	Exhibits	12
Signatures		13

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SKINOVATION PHARMACEUTICAL INCORPORATED

Condensed Financial Statements

~~June~~September 30, 2024

(Unaudited)

Skinovation Pharmaceutical Incorporated

Condensed Balance Sheets

(Unaudited)


	September 30, 2024			December 31, 2023
		(Unaudited)
ASSETS
Current Assets
Cash	$	1,844		$	16,234
Total Current Assets		1,844			16,234
Total Assets	$	1,844		$	16,234

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable	$	10,500		$	6,000
Notes payable		286,021			286,021
Accrued interest		188,574			171,414
Total Current Liabilities		485,095			463,435
Total Liabilities		485,095			463,435
Commitments and Contingencies		—			—
Stockholders’ Deficit
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding		—			—
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding		708			708
Additional paid-in capital		25,148			25,148
Accumulated deficit		(509,107	)		(473,057	)
Total Stockholders' Deficit		(483,251	)		(447,201	)
Total Liabilities and Stockholders' Deficit	$	1,844		$	16,234

	JUNE 30, 2024			DEC 31, 2023
ASSETS
Current Assets
Cash	$	5,234		$	16,234
Total Current Assets		5,234			16,234
Total Assets	$	5,234		$	16,234
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable	$	9,000		$	6,000
Notes payable		286,021			286,021
Accrued interest		182,854			171,414
Total Current Liabilities		477,875			463,435
Total Liabilities		477,875			463,435
Commitments and Contingencies		—			—
Stockholders' Deficit
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding		—			—
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding		708			708
Additional paid-in capital		25,148			25,148
Accumulated deficit		(498,497	)		(473,057	)
Total Stockholders' Deficit		(472,641	)		(447,201	)
Total Liabilities and Stockholders' Deficit	$	5,234		$	16,234

The accompanying notes are an integral part of these unaudited condensed financial statements.

Skinovation Pharmaceutical Incorporated

Condensed Statements of Operations

(Unaudited)

	FOR THE THREE MONTHS ENDED JUNE 30, 2024			FOR THE THREE MONTHS ENDED JUNE 30, 2023			FOR THE SIX MONTHS ENDED JUNE 30, 2024			FOR THE SIX MONTHS ENDED JUNE 30, 2023
	FOR THE THREE MONTHS ENDED September 30, 2024			FOR THE THREE MONTHS ENDED September 30, 2023			FOR THE NINE MONTHS ENDED September 30, 2024			FOR THE NINE MONTHS ENDED September 30, 2023
REVENUES	$	—		$	—		$	—		$	—
OPERATING EXPENSES
General and administrative		34,~~949~~890			2,~~910~~899			1418,~~000~~890			811,~~630~~529
TOTAL EXPENSES		34,~~949~~890			2,~~910~~899			1418,~~000~~890			811,~~630~~529
Loss from operations		(34,~~949~~890	)		(2,~~910~~899	)		(1418,~~000~~890	)		(811,~~630~~529	)
OTHER INCOME (EXPENSE)
Interest expense		(5,720	)		(5,~~280~~038	)		(1117,~~440~~160	)		(1015,~~340~~378	)
Total other income (expense)		(5,720	)		(5,~~280~~038	)		(1117,~~440~~160	)		(1015,~~340~~378	)
LOSS BEFORE INCOME TAXES		(910,~~669~~610	)		(87,~~190~~937	)		(2536,~~440~~050	)		(1826,~~970~~907	)
INCOME TAX EXPENSE		—			—			—			—
NET LOSS	$	(910,~~669~~610	)	$	(87,~~190~~937	)	$	(2536,~~440~~050	)	$	(1826,~~970~~907	)
Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)	$	(0.0405	)	$	(0.0304	)
Basic and diluted weighted average shares outstanding		708,000			708,000			708,000			708,000

The accompanying notes are an integral part of these unaudited condensed financial statements.

Skinovation Pharmaceutical Incorporated

Condensed Statements of Stockholders’ Deficit

For the three and ~~six~~nine months ended (Unaudited) ~~June~~September 30, 2024 and 2023

					Additional					Total
	Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance – December 31, 2022		708,000	$	708	$	25,148	$	(437,191	)	$	(411,335	)
Net loss for the three months ended March 31, 2023		—		—		—		(10,780	)		(10,780	)
Balance – March 31, 2023		708,000	$	708	$	25,148	$	(447,971	)	$	(422,115	)
Net loss for the three months ended June 30, 2023		—		—		—		(8,190	)		(8,190	)
Balance – June 30, 2023		708,000	$	708	$	25,148	$	(456,161	)	$	(430,305	)
Net loss for the three months ended September 30, 2023		—		—		—		(7,937	)		(7,937	)
Balance – September 30, 2023		708,000	$	708	$	25,148	$	(464,098	)	$	(438,242	)
Balance – December 31, 2023		708,000	$	708	$	25,148	$	(473,057	)	$	(447,201	)
Net loss for the three months ended March 31, 2024		—		—		—		(15,771	)		(15,771	)
Balance – March 31, 2024		708,000	$	708	$	25,148	$	(488,828	)	$	(462,972	)
Net loss for the three months ended June 30, 2024		—		—		—		(9,669	)		(9,669	)
Balance – June 30, 2024		708,000	$	708	$	25,148	$	(498,497	)	$	(472,641	)
Net loss for the three months ended September 30, 2024		—		—		—		(10,610	)		(10,610	)
Balance – September 30, 2024		708,000	$	708	$	25,148	$	(509,107	)	$	(483,251	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Skinovation Pharmaceutical Incorporated

Condensed Statements of Cash Flows

(Unaudited)

	FOR THE SIX MONTHS ENDED JUNE 30, 2024			FOR THE SIX MONTHS ENDED JUNE 30, 2023
	FOR THE NINE MONTHS ENDED September 30, 2024			FOR THE NINE MONTHS ENDED September 30, 2023
Cash Flows from Operating Activities
Net loss	$	(2536,~~440~~050	)	$	(1826,~~970~~907	)
Adjustments to reconcile net loss to cash used by operating activities:
Changes in operating assets and liabilities:
Increase in accounts payable		34,~~000~~500			34,~~000~~500
Increase in accrued interest		~~11,440~~			~~10,340~~
Net cash used by operating activities		(1114,~~000~~390	)		(57,~~630~~029	)
Cash Flows from Investing Activities
Net cash used by investing activities		—			—
Cash Flows from Financing Activities
Proceeds from notes payable		—			916,~~000~~500
Net cash provided by financing activities		—			916,~~000~~500
Net increase (decrease) in cash		(1114,~~000~~390	)		39,~~370~~471
Cash at beginning of period		16,234			163
Cash at end of period	$	51,~~234~~844		$	39,~~533~~634
Supplemental Cash Flow Information:
Cash paid for interest	$	—		$	—
Cash paid for income taxes	$	—		$	—

The accompanying notes are an integral part of these unaudited condensed financial statements.

SKINOVATION PHARMACEUTICAL INCORPORATED

Notes to the Unaudited Condensed Financial Statements

~~June~~September 30, 2024

NOTE 1 – CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended ~~June~~September 30, 2024, and for all periods presented have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2023, audited financial statements as reported in its Form 10-K. The results of operations for the period ended ~~June~~September 30, 2024, are not necessarily indicative of the operating results for the full year ended ~~December~~ December 31, 2024.

NOTE 2 – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

NOTE 3 – ACCOUNTS AND NOTES PAYABLE

At ~~June~~September 30, 2024, and December 31, 2023, the ~~Company~~ Company had accounts payable of $910,~~000~~500 and $6,000, respectively, and notes payable of $286,021 and $286,021, respectively, for services as well as cash advances received from unrelated parties. The notes payable bear interest at 8% and are due on demand.

Accrued interest on the notes was $~~182~~188,~~854~~574 and $171,414 at ~~June~~September 30, 2024 , and December 31, 2023, respectively.

NOTE 4 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

In this report references to “Skinovation,” “we,” “us,” and “our” refer to Skinovation Pharmaceutical Incorporated.

FORWARD LOOKING STATEMENTS

The U. S. Securities and Exchange Commission (“SEC”) ~~encourages~~ encourages reporting companies to disclose forward-looking information so that investors can better understand future prospects and make ~~informed~~ informed investment decisions. This report contains these types of statements. Words such as “may,” “expect,” “believe,” “intend,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Executive Overview

We have not recorded revenues from operations since inception, and we are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise substantial doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue.

As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may complete a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.

We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.

If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will sell our ~~common~~Common ~~stock~~Stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our ~~common stock~~Common Stock, then our stockholders may experience dilution in the value per share of their ~~common~~Common ~~stock~~Stock.

Liquidity and Capital Resources

We have not recorded revenues from operations during 2024 and 2023 and have not established an ongoing source of revenue sufficient to cover our operating costs. We expect to rely upon third parties to pay for our operating expenses. At ~~June~~September 30, 2024, we had cash of $51,~~234~~844 compared to $16,234 cash at December 31, 2023. Our total liabilities increased to $~~477~~485,~~875~~095 at ~~June~~September 30, 2024, from $463,435 at December 31, 2023. The increase in total liabilities is primarily due to accounts payable and notes payable for professional fees and accrued interest.

We intend to obtain capital from management, significant stockholders and third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability for the long term.

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through advances and loans provided by management, significant stockholders or third parties. We may also rely on the issuance of our ~~common~~Common ~~stock~~Stock in lieu of cash to convert debt or pay for expenses.

Results of Operations

We did not record revenues from operations in either 2024 or 2023. We recorded $1418,~~000~~ 890 in general and administrative expenses for the ~~six~~nine months ended ~~June~~September 30, 2024 ~~(“2024 six-month period”)~~ compared to $811,~~630~~529 for the ~~six~~nine months ended ~~June~~September 30, 2023 ~~(“2023 six-month period”)~~. We recorded $34,~~949~~890 in general and administrative expenses for the three months ended ~~June~~ September 30, 2024 ~~(“2024 second quarter”)~~ compared to $2,~~910~~899 the three months ended ~~June~~September 30, 2023 ~~(“2023 second quarter”)~~.

Total other expense increased to $1117,~~440~~160 for the September 30, 2024 ~~six~~Nine-~~month~~Month ~~period~~ Period compared to $1015,~~340~~378 for the September 30, 2023 ~~six~~Nine-~~month~~Month ~~period~~Period. Total other expense increased to $5,720 for the September 30, 2024 ~~second~~Third ~~quarter~~Quarter compared to $5,~~280~~ 038 for the September 30, 2023 ~~second~~Third ~~quarter~~Quarter. Total other expense represents interest expense on notes payable.

Our net loss for the September 30, 2024 ~~six~~Nine-~~month~~Month ~~period~~Period increased to $2536,~~440~~050 compared to $1826,~~970~~907 orfor the September 30, 2023 ~~six~~Nine-~~month~~Month ~~period~~Period. Our net loss for the September 30, 2024 ~~second~~Third ~~quarter~~Quarter increased to $910,~~669~~610 compared to $87,~~190~~937 for the September 30, 2023 ~~second~~ ~~quarter~~Third Quarter. Management expects net losses to continue until we acquire or merge with a business opportunity.

Commitments and Obligations

~~June~~At September 30, 2024, we had outstanding notes payable totaling $286,021. All of the notes payable are non-collateralized, carry interest at 8% and are due on demand. We owed total accrued interest at ~~June~~September 30, 2024 , of $~~182~~188,~~854~~574.

At ~~June~~September 30, 2024, accounts payable for consulting services and professional services provided or paid for by third parties totaled $910,~~000~~500.

Two lenders represent in excess of 95% of the Company’s ~~accounts~~ accounts payable and notes payable at ~~June~~September 30, 2024.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Emerging Growth Company

We qualify as an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). A company qualifies as an emerging growth company if it has total annual gross revenues of less than $1.07 billion during its most recently completed fiscal year and, as of December 8, 2011, had not sold common equity securities under a registration statement. Under the JOBS Act we are permitted to, and intend to, rely on exemptions from certain disclosure requirements.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were not effective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

Changes to Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the quarter ended ~~June~~September 30, 2024, that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our ~~directors~~ Directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

ITEM 1A. RISK FACTORS

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Part I Exhibits

No.	Description
31.1	Principal Executive Officer Certification
31.2	Principal Financial Officer Certification
32.1	Section 1350 Certification

Part II Exhibits

No.	Description
3(i)	Wyoming Articles of Domestication, filed November 23, 2016 (Incorporated by reference to exhibit 3(i).2 of Form 10-K, filed March 20, 2017)
3(ii)	Bylaws of Skinovation (Incorporated by reference to exhibit 3(ii) of Form 10-K, filed March 20, 2017)
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Label Linkbase Document
101.PRE	XBRL Taxonomy Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: ~~August~~November 1221, 2024 SKINOVATION PHARMACEUTICAL INCORPORATED By: /s/ Hugo Rodier Hugo Rodier President and Director Principal Financial Officer

Filing Compare · SKINOVATION PHARMACEUTICAL INC